Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
Phase 4 N=86 Maintenance Treatment of Bipolar Depression
Bipolar Disorder · Depression
Primary: Mania Rating Scale — 4.54; 5.57 units on a scale
Phase 4 N=189 Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
Bipolar Disorder · Major Depression
Primary: HAM-D 17 Item: Hamilton Depression Rating Scale — 6.6; 4.91; 2.333; 3.75 score on a scale
Phase 3 N=57 Lamotrigine for Symptoms of Geriatric Bipolar Depression
Bipolar Disorder · Depression, Bipolar
Primary: Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) — -15.5 units on a scale — p=<.01
N/A N=44 Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Depression, Bipolar · Bipolar Disorder · Mood Disorders
Primary: Number of Participants With Clinical Response [ Time Frame: At 6 Weeks Following Course of tDCS Treatment ] — 34 Participants
N/A N=21 Depression, Obesity and Inflammatory Markers
Bipolar Disorder · Depression · Obesity
Primary: Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8 — -12.2; -12.0 units on a scale — p=<0.05
Phase 4 N=40 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
Bipolar Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -39.24 Percent change in MADRS from baseline
Phase 3 N=119 Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Bipolar Disorder · Bipolar Depression
Primary: MADRS Rating Scale Change — 13.1; 15.2 units on a scale — p=0.17
Phase 4 N=129 Antidepressant Therapy in Treating Bipolar Type II Major Depression
Bipolar Disorder · Depression
Primary: Depressive Relapse — 3; 4 Participants
Phase 4 N=92 Acute Psychotherapy for Bipolar II Depression
Bipolar Disorder · Depression
Primary: Remission — 16; 13 Participants — p=<0.0001
N/A N=14 Riluzole in the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change in Hamilton Depression Rating Scale — -12.6 units on a scale — p=<.001
Phase 2 N=94 A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression
Bipolar Disorder
Primary: Mean Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to the End of 8 Weeks of Therapy. — 32.4; 30.4; 21.7; 19.0 units on a scale
N/A N=35 Levetiracetam in the Management of Bipolar Depression
Bipolar Depression
Primary: Change in Hamilton Depression Rating Scale (HDRS-21) Total Score From Baseline at Week 6. — -2.7647; -4; -3.4259; -6.5875 score on scale — p=0.29
Phase 4 N=65 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
Bipolar Depression
Primary: Response to Treatment — 21; 9; 6; 11 Participants — p=.02
Phase 4 N=177 Prevention of Relapse & Recurrence of Bipolar Depression
Bipolar Disorder
Primary: Number of Participants With Relapse of Major Depressive Episode Within 1 Year — 4; 5 Participants
Phase 4 N=7 Tranylcypromine Treatment of Bipolar Depression
Bipolar Disorder I or II
Primary: 29 Item Hamilton Rating Scale for Depression (HamD29) — 27.0; 5.8 Hamilton Depression score
Phase 3 N=525 A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
Bipolar Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -10.6; -13.6; -12.6 units on a scale — p=0.007
Phase 3 N=514 Olanzapine Treatment of Patients With Bipolar I Disorder
Depression, Bipolar
Primary: Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) — 29.36; 28.69; -14.26; -11.71 units on a scale — p=0.018
Phase 3 N=25 Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
Bipolar II Disorder
Primary: Number of Participants With Greater Than or Equal to 50% Reduction in Depression Scores, With a Mania Score Less Than or Equal to 10 — 4; 3; 10; 8 participants
Phase 2 N=50 Scopolamine in Bipolar Depression
Bipolar Disorder Depression
Primary: Hamilton Depression Rating Scale Score After Last Treatment — 12.0; 13.0 units on a scale — p=0.3
Phase 2 N=116 A Study of JNJ-55308942 in the Treatment of Bipolar Depression
Bipolar Disorder
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6 — -16.0; -15.4 Units on a scale — p==0.438
Phase 3 N=356 Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -11.8; -10.4 units on a scale — p=0.176
Phase 2 N=60 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
Bipolar Depression
Primary: Baseline and Week 12 Montgomery-Asberg Depression Rating Scale (MADRS) Scores — 29.61; 27.79; 18.64; 16.06 units on a scale
Phase 4 N=1 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
Bipolar Depression
Primary: Montgomery Asberg Depression Rating Scale — 34 units on a scale
Phase 3 N=11 Liothyronine (T3) for Bipolar Depression
Depression · Bipolar Disorder
Primary: Hamilton Rating Scale for Depression Scores — 3.50; 7.25 units on a scale
Phase 3 N=62 Bipolar Depression Before and After Lamotrigine Treatment
Bipolar Depression
Primary: Mean Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Baseline for Both Groups, and After 12 Weeks of Lamotrigine Monotherapy for the Bipolar Group — 27.79…
Phase 3 N=554 Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.9; -20.7; -19.7 score on a scale — p=0.514
N/A N=33 Vitamin D Supplementation for Bipolar Depression
Bipolar Disorder · Bipolar Depression
Primary: Change in Montgomery-Åsberg Depression Rating Scale — 9.4; 6.4 units on a scale — p=0.89
Phase 3 N=348 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -17.1; -13.5 units on a scale — p=0.005